CAR T-Cell Therapy With Axi-Cel Holds Promise in R/R Indolent NHL
May 30th 2020Interim analysis of the ZUMA-5 study indicates that patients with relapsed or refractory indolent non-Hodgkin lymphoma who were treated with the chimeric antigen receptor T-cell therapy of axicabtagene ciloleucel had high rates of response and demonstrated the agent's manageable safety profile.
Read More
Efficacy of Cabozantinib in Previously Treated RCC Is Consistent Irrespective of Prior Therapy
May 30th 2020An analysis of patients with advanced renal cell carcinoma revealed that systemic therapy with cabozantinib induced reliable responses for patients regardless of whether or not they had received prior immunotherapy, according to data that were presented as part of the 2020 American Society of Clinical Oncology Virtual Scientific Program.
Read More
HER2+ Colorectal and Gastric/GEJ Cancers Demonstrate Responses to Fam-Trastuzumab Deruxtecan Therapy
May 30th 2020Data from 2 phase 2 trials involving fam-trastuzumab deruxtecan-nxki revealed the agent’s ability to induce responses in patients with HER2-positive metastatic colorectal cancer and advanced gastric or gastroesophageal junction adenocarcinoma.
Read More
Teclistamab Appears Safe, Efficacious in Relapsed/Refractory Multiple Myeloma
May 30th 2020Another treatment option would be a welcome change for these patients, who tend to have poor prognoses once they run out of treatment options, according to Saad Z. Usmani, MD. After becoming refractory to available therapies, median overall survival is 6-11 months.
Read More
Apalutimide Combo Significantly Improves Survival Outcomes in nmCRPC
May 30th 2020Apalutimide in combination with androgen deprivation therapy led to a significant improvement in overall survival in patients with nonmetastatic castration-resistant prostate cancer in the phase 3 SPARTAN clinical trial.
Read More
Survival Benefit Continues With Encorafenib Plus Binimetinib in BRAF V600E+ Melanoma
May 30th 2020Encorafenib plus binimetinib show sustained overall survival and progression-free survival benefit in patients with BRAF V600–mutant melanoma, according to updated findings from the COLUMBUS study.
Read More
Encorafenib/Cetuximab Combos Sustain OS Benefit in BRAF+ Metastatic Colorectal Cancer
May 30th 2020Encorafenib plus cetuximab with or without binimetinib continued to show an overall survival benefit compared with cetuximab plus irinotecan-based regimens as treatment of patients with BRAF-mutated metastatic colorectal cancer in the updated findings from the phase 3 BEACON CRC clinical trial.
Read More
First-in-Human Study Shows Favorable Activity With CC-92480 in Relapsed/Refractory Myeloma
May 30th 2020Favorable activity and safety findings were demonstrated with the combination of CC-92480 plus dexamethasone as treatment of patients with heavily pretreated relapsed or refractory multiple myeloma in an ongoing study, according to a presentation from the 2020 American Society of Clinical Oncology Virtual Scientific Program.
Read More
PyL PET Tracer May Be Superior to Standard Imaging for Prostate Cancer
May 30th 2020"The CONDOR study met its primary endpoint. Indeed, it well exceeded it. And it demonstrated excellent diagnostic performance of PyL PET in men with biochemically relapsed prostate cancer, even at very low PSA values."
Read More
High Rate of Responses Seen With Ide-cel in Heavily Pretreated Myeloma
May 30th 2020“Ide-cel demonstrated frequent, deep, and durable responses in heavily pretreated, highly relapsed/refractory patients with myeloma. Overall, ide-cel provides an attractive option for the treatment of patients with triple-class exposed relapsed/refractory myeloma."
Read More
Frontline Pembrolizumab Plus Chemo Shows Compelling PFS Improvement in PD-L1+ TNBC
May 29th 2020"Pembrolizumab and chemotherapy demonstrated a statistically significant and clinically meaningful improvement in PFS as compared with chemotherapy alone for the first-line treatment of metastatic TNBC with a PD-L1 CPS of 10 or higher tumors."
Read More
OS Benefit Observed With Frontline Nivolumab/Ipilimumab Plus Limited Chemotherapy in NSCLC
May 29th 2020"CheckMate 9LA met its primary end point of overall survival at the pre-planned interim analysis…With early separation of overall survival curves and lower progressive disease rates as best overall response, the hypothesis for this study design was validated."
Read More
The addition of tucatinib to treatment with trastuzumab and capecitabine resulted in more than a 60% reduction in the risk of central nervous system progression or death in both patients with previously treated HER2-positive metastatic breast cancer who have active or stable brain metastases.
Read More
Modest survival benefits were observed in patients with extensive-stage small cell lung cancer who received the combination of pembrolizumab and etoposide plus platinum compared with patients who received EP and placebo. Although progression-free survival rates reached the threshold for significance, overall survival rates failed to reach the prespecified threshold, according to data from the phase 3 KEYNOTE-604 trial.
Read More
Responses to Olaparib/Cediranib Combination in Ovarian Cancer Warrant Further Investigation
May 29th 2020Despite missing the primary end point of progression-free survival improvement, cediranib and olaparib demonstrated comparable activity with platinum-based chemotherapy in patients with recurrent platinum-sensitive ovarian cancer.
Read More
Alpelisib Generates Promising Responses in PI3KCA+ Breast Cancer After Progression on CDK Inhibitor
May 29th 2020“Preliminary data for the 18 patients who have received belantamab mafodotin 2.5 mg/kg single dosing with bortezomib/dexamethasone suggests that this combination has an acceptable safety profile with no new safety signals identified."
Read More
Deep and Durable Responses Still Observed With JNJ-4528 in Relapsed/Refractory Myeloma
May 29th 2020According to the lead study author Jesus G. Berdeja, MD, the overall response rate was 100%, with a stringent complete response rate of 86%. Further, the progression-free survival rate was 86% at 9 months.
Read More
Durable Responses Elicited with Nivolumab Plus Ipilimumab in Advanced NSCLC
May 29th 2020"Based on these results, we note that the combination of nivolumab and ipilimumab, which is now approved by the United States FDA, is a novel chemotherapy-sparing first-line treatment approach for advanced-stage non-small-cell lung cancer."
Read More
Novel LuPSMA Appears More Active in Metastatic Castration-Resistant Prostate Cancer
May 29th 2020“Lu-PSMA is a novel class of therapy with high activity and relatively low toxicity, consistent with the results of prior single-center studies in phase II data. Lu-PSMA appears to represent a favorable treatment option compared to cabazitaxel in a selected population with high PSMA-expression.”
Read More
Positive Zanubrutinib Data May Spark Change for Treatment of Waldenstrom Macroglobulinemia
May 29th 2020"The totality of data from the two trials presented at ASCO suggests that zanubrutinib may be a preferred treatment option for patients with WM, regardless of whether they have received prior treatment."
Read More